Literature DB >> 22198951

Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles.

Joris van der Heijden1, Willemijn B Breunis, Judy Geissler, Martin de Boer, Timo K van den Berg, Taco W Kuijpers.   

Abstract

The balance between activating and inhibitory signals from the different FcγRs for IgG ensures homeostasis of many inflammatory responses. FCGR2C is the product of an unequal crossover of the FCGR2A and FCGR2B genes encoding the activating FcγRIIa (CD32a) and inhibitory FcγRIIb (CD32b), respectively. A single nucleotide polymorphism (SNP) in exon 3 of FCGR2C results in either expression of the activating FcγRIIc (CD32c) (FCGR2C-open reading frame [ORF]) or its absence because of a stop codon (FCGR2C-Stop). Two additional variations in FcγRIIb/c expression on leukocytes have now been identified. In case of "nonclassical" FCGR2C-ORF alleles, FcγRIIc expression was unexpectedly absent, because of novel splice site mutations near exon 7 leading to another stop codon. In some individuals with FCGR2C-Stop alleles FcγRIIb was detected on NK cells, which normally are devoid of this protein. Individuals with these nonclassical FCGR2C-Stop alleles carried a deletion of FCGR2C-FCGR3B that extends into the promoter region of the adjacent FCGR2B gene and probably deletes a negative regulatory element in the FCGR2B promoter in NK cells. FcγRIIb expression on NK cells effectively inhibited killing mediated by FcγRIIIa (CD16a) in Ab-dependent cytotoxicity tests. Our findings demonstrate a more extensive and previously unnoticed variation in FcγR expression with relevance to immunity and inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198951     DOI: 10.4049/jimmunol.1003945

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia.

Authors:  S Audia; K Santegoets; A G Laarhoven; G Vidarsson; O Facy; P Ortega-Deballon; M Samson; N Janikashvili; P Saas; B Bonnotte; T R Radstake
Journal:  Clin Exp Immunol       Date:  2017-02-28       Impact factor: 4.330

2.  Fc-dependent mechanisms of action: roles of FcγR and FcRn.

Authors:  T Kuijpers
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

3.  FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.

Authors:  Julien Lejeune; Benoît Piègu; Valérie Gouilleux-Gruart; Marc Ohresser; Hervé Watier; Gilles Thibault
Journal:  MAbs       Date:  2012-10-02       Impact factor: 5.857

Review 4.  Fc receptors as adaptive immunoreceptors.

Authors:  Marc Daëron
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

5.  FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.

Authors:  Amy K Erbe; Wei Wang; Jacob Goldberg; Mikayla Gallenberger; KyungMann Kim; Lakeesha Carmichael; Dustin Hess; Eneida A Mendonca; Yiqiang Song; Jacquelyn A Hank; Su-Chun Cheng; Sabina Signoretti; Michael Atkins; Alexander Carlson; James W Mier; David J Panka; David F McDermott; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2016-10-14       Impact factor: 12.531

6.  Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses.

Authors:  Xinrui Li; Jianming Wu; Travis Ptacek; David T Redden; Elizabeth E Brown; Graciela S Alarcón; Rosalind Ramsey-Goldman; Michelle A Petri; John D Reveille; Richard A Kaslow; Robert P Kimberly; Jeffrey C Edberg
Journal:  Sci Transl Med       Date:  2013-12-18       Impact factor: 17.956

7.  Nonallelic homologous recombination of the FCGR2/3 locus results in copy number variation and novel chimeric FCGR2 genes with aberrant functional expression.

Authors:  S Q Nagelkerke; C E Tacke; W B Breunis; J Geissler; J W R Sins; B Appelhof; T K van den Berg; M de Boer; T W Kuijpers
Journal:  Genes Immun       Date:  2015-07-02       Impact factor: 2.676

8.  FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

Authors:  Shuying S Li; Peter B Gilbert; Georgia D Tomaras; Gustavo Kijak; Guido Ferrari; Rasmi Thomas; Chul-Woo Pyo; Susan Zolla-Pazner; David Montefiori; Hua-Xin Liao; Gary Nabel; Abraham Pinter; David T Evans; Raphael Gottardo; James Y Dai; Holly Janes; Daryl Morris; Youyi Fong; Paul T Edlefsen; Fusheng Li; Nicole Frahm; Michael D Alpert; Heather Prentice; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Merlin L Robb; Robert J O'Connell; Barton F Haynes; Nelson L Michael; Jerome H Kim; M Juliana McElrath; Daniel E Geraghty
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

9.  Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques.

Authors:  Kara Jensen; Rafiq Nabi; Koen K A Van Rompay; Spencer Robichaux; Jeffrey D Lifson; Michael Piatak; William R Jacobs; Glenn Fennelly; Don Canfield; Katie R Mollan; Michael G Hudgens; Michelle H Larsen; Angela M Amedee; Pamela A Kozlowski; Kristina De Paris
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

Review 10.  CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity.

Authors:  Eugenia Corrales-Aguilar; Katja Hoffmann; Hartmut Hengel
Journal:  Semin Immunopathol       Date:  2014-10-07       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.